Seeking Alpha on MSN24m
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...
Finanznachrichten49m
Lexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
The Company is also announcing that clinical test article manufacturing for all planned Study ... President of Lexaria Bioscience Corp. "Their nearly round-the-clock work has resulted in a rapid ...